THRX/GSK—Relovair is not shaping up to be a shoo-in for the “Son of Advair” that GSK was hoping for when it inked the development deal for this product:
The new once-a-day inhaled medicine showed superiority to GSK's existing twice-daily drug Advair in one trial for chronic lung disease, but not another. That patchy record echoes results of other studies in an extensive development program.
THRX is nevertheless up slightly in trading today. The data could have been a lot worse.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.